LUV RT

A C20-acylated 39-residue synthetic peptide characterized in cryo-EM structural studies of class B GPCR complexes.

View Luv RT in the store

Molecular Profile

Type
Synthetic peptide (acylated, 39 residues)
Molecular formula
C221H342N46O68
Molecular weight
~4,731 Da
CAS number
2381089-83-2
Amino acids
39
Fatty acid chain
C20 diacid
Modification
Aib at positions 2 and 20; α-methyl-Leu at position 13; C-terminal amide; Lys17-linked C20 fatty-diacid acylation via a γ-Glu/AEEA linker.

Mechanism & Target Class

A C20-acylated 39-residue synthetic peptide. Cryo-EM studies of LUV RT bound to its class B GPCR–Gs complexes reveal a continuous α-helical conformation in which the N-terminal segment inserts into the receptor transmembrane bundle and the central segment contacts the extracellular loops. Non-standard residues (Aib, α-methyl-Leu) confer protease resistance; the C20 fatty-diacid side chain confers reversible albumin binding, extending circulatory half-life.

Storage & Handling

Lyophilized
-20°C (-80°C long term); powder typically stable ~24 months.
Handling
Aliquot to avoid freeze-thaw; protect from light; keep sealed and dry.

Primary Database

PubChem CID 171390338 ↗

References (21)

  1. Reviews

    1

    Gutgesell RM, Nogueiras R, Tschöp MH, Müller TD. (2024). Diabetes Therapy

    DOI: 10.1007/s13300-024-01566-x

  2. 2

    Misra S, et al. (2025). J Basic Clin Physiol Pharmacol

    DOI: 10.1515/jbcpp-2025-0113PubMed 40728138

  3. 3

    Systematic review & meta-analysis (2025). PubMed

    PubMed 39817343

  4. 4

    Pasqualotto E, et al. (2024). Metabolism Open

    DOI: 10.1016/j.metop.2024.100321

  5. 5

    Doggrell SA. (2023). Expert Opin Investig Drugs

    DOI: 10.1080/13543784.2023.2206560PubMed 37086147

  6. 6

    Kaur M, Misra S. (2024). Eur J Clin Pharmacol

    DOI: 10.1007/s00228-024-03646-0PubMed 38367045

  7. 7

    Ray A. (2023). Expert Opin Investig Drugs

    DOI: 10.1080/13543784.2023.2276754PubMed 37902090

  8. 8

    Tetelbaum L, Mullally JA, Frishman WH. (2024). Cardiol Rev

    DOI: 10.1097/CRD.0000000000000793PubMed 39724554

  9. 9

    Sinha B, Ghosal S. (2025). Obesity (Silver Spring)

    DOI: 10.1002/oby.24360PubMed 40685589

  10. Clinical

    10

    Coskun T, et al. (2025). Lancet Diabetes & Endocrinology

    DOI: 10.1016/S2213-8587(25)00092-0

  11. 11

    Giblin K, et al. (2026). Diabetes, Obesity and Metabolism

    DOI: 10.1111/dom.70209

  12. 12

    Sanyal AJ, et al. (2024). Nature Medicine

    DOI: 10.1038/s41591-024-03018-2PubMed 38858523

  13. 13

    Urva S, et al. (2023). Diabetes, Obesity and Metabolism

    DOI: 10.1111/dom.15167

  14. 14

    Rosenstock J, et al. (2023). The Lancet

    DOI: 10.1016/S0140-6736(23)01053-XPubMed 37385280

  15. 15

    Jastreboff AM, et al. (2023). NEJM

    DOI: 10.1056/NEJMoa2301972PubMed 37366315

  16. 16

    Urva S, et al. (2022). The Lancet

    DOI: 10.1016/S0140-6736(22)02033-5PubMed 36354040

  17. Primary research

    17

    Briand F, et al. (2025). Obesity

    DOI: 10.1002/oby.70155

  18. 18

    Marathe SJ, et al. (2025). npj Metabolic Health and Disease

    DOI: 10.1038/s44324-025-00054-5

  19. 19

    Li W, et al. (2024). Cell Discovery

    DOI: 10.1038/s41421-024-00700-0PubMed 39019866

  20. 20

    Regmi A, Roell W. (2023). STAR Protocols

    DOI: 10.1016/j.xpro.2023.102304PubMed 37178114

  21. 21

    Coskun T, et al. (2022). Cell Metabolism

    DOI: 10.1016/j.cmet.2022.07.013